Is JNJ Stock A Buy On CEO's Bullish Call For Coronavirus Vaccine? [Investor's Business Daily]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Investors Business Daily
Johnson & Johnson stock is under pressure amid the coronavirus correction. Further, it's facing litigation tied to opioids and talcum powder. Is now the time to invest in JNJ stock? The post Is JNJ Stock A Buy On CEO's Bullish Call For Coronavirus Vaccine? appeared first on Investor's Business Daily .
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Health Canada issues NOC to J&J's CARVYKTI for multiple myeloma [Yahoo! Finance]Yahoo! Finance
- 340B Legal Challenges Highlight The Appetite For Innovation That Supports The Program's Goals [Forbes]Forbes
- Antihistamine Drugs Industry Report 2025-2030: A $381 Million Opportunity - Johnson & Johnson, Sanofi, Pfizer, and Bayer Experiencing Notable Growth Driven by Substantial R&D Investments [Yahoo! Finance]Yahoo! Finance
- Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA® (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor [Yahoo! Finance]Yahoo! Finance
- Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA® (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitorPR Newswire
JNJ
Earnings
- 10/15/24 - Beat
JNJ
Sec Filings
- 11/13/24 - Form 13F-HR
- 11/6/24 - Form 25-NSE
- 10/31/24 - Form 4/A
- JNJ's page on the SEC website